Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 3Phase 1 3Phase 2/3 2Phase 3 1

Status

Unknown 18Completed 9Recruiting 5Terminated 4Withdrawn 3Not yet recruiting 3Active not recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1Dermatologic 1

Conditions

Skin Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × toripalimab × Clear all
NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

University of Southern California

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Skin Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Tumor-Agnostic

Neoplasms

NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 1 Active not recruiting
53 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡